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Aims This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa
in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa
will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure,
and improve other outcomes.
Methods
and results
Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with
those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled
more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had
diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate ,60 mL/min/1.73 m2). Patients
in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and
more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and
pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific
inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.
Conclusion The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive
co-morbidity.
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Introduction
Numerous studies have shown that anaemia is common in heart
failure and is associated with worse outcomes.1– 8 While some
patients have specific, correctable causes of anaemia such as iron
deficiency, the exact aetiology of anaemia in most patients with
heart failure is unknown, although contributing mechanisms may
include renal impairment, inflammation, inadequate production
of erythropoietin, and unresponsiveness to erythropoietin.9 –12
Heart failure patients with anaemia have more severe symptoms
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and signs, reduced functional capacity, and higher rates of hospital-
ization and death, compared with heart failure patients without
anaemia.1– 8,13,14 If anaemia is a mediator and not just a marker
of poor outcomes, correcting anaemia could become an important
and novel therapeutic target to improve long-term outcomes in
such patients. As a result, there has been much interest in
whether correcting anaemia might improve outcomes in heart
failure.15,16 One treatment shown to increase haemoglobin in
anaemic patients with heart failure is the use of an erythropoiesis-
stimulating agent (ESA).17– 22 Studies in experimental animals have
also raised the hypothesis that ESAs might also have other poten-
tially beneficial cardiovascular effects.23– 25 However, it is not
known whether ESAs improve clinical outcomes in heart failure,
and they have not been shown to reduce cardiovascular events in
patients with chronic kidney disease.26–28 The Reduction of Events
with Darbepoetin alfa in Heart Failure trial (RED-HF) is testing the hy-
pothesis that anaemia correction with the ESA darbepoetin will
reduce the composite endpoint of death from any cause or hospital
admission for worsening heart failure, and improve quality of life
and other outcomes.29–31 This report describes the baseline charac-
teristics of the patients randomized in RED-HF and considers them in
the context of other recently published heart failure trials.
Methods
Objectives
RED-HF is a randomized multicentre double-blind, placebo-controlled,
clinical trial designed to determine whether correction of anaemia with
the long-acting ESA darbepoetin alfa improves mortality and morbidity
in patients with heart failure and anaemia. The details of the design of
RED-HF have been described in detail elsewhere.30 The primary compos-
ite outcome is death from any cause or hospitalization for heart failure;
change in health-related quality of life, measured using the Overall
Summary Score and Symptom Frequency Score from the Kansas City
Cardiomyopathy Questionnaire (KCCQ), is a key secondary endpoint.32
Briefly, consenting patients aged ≥ 18 years, in NYHA functional
class II– IV, with an LVEF ≤ 40% were eligible if their haemoglobin
was between 90 and 120 g/L and they were receiving optimal standard
heart failure therapy. Major exclusion criteria included transferrin sat-
uration (TSAT) ,15%, evidence of bleeding or other correctable
causes of anaemia, serum creatinine .265 mmol/L (.3.0 mg/dL),
and blood pressure .160/100 mmHg. Informed consent was obtained
before any study-specific procedure. Patients were randomized 1:1 to
double-blind subcutaneous placebo or darbepoetin alfa dosed to a
haemoglobin target of 130 g/L (and not exceeding 145 g/L). Random-
ization was stratified by region and by the presence or absence of
an implantable cardioverter defibrillator (ICD), and/or CRT.
Statistical analysis
The RED-HF is an event-driven study, such that assuming an annualized
placebo event rate of 25%. Approximately 1150 subjects with primary
endpoint events will be needed to detect a 20% difference between
treatment groups with 80% power with adjustments for treatment
effect attenuation. The protocol originally assumed that the study
would enrol approximately 2600 subjects. Because the actual enrolment
duration was longer than originally anticipated, 2278 subjects were actu-
ally enrolled to accrue the approximately 1150 primary endpoints.
All randomized subjects are included in the present analysis.
Descriptive summary statistics in the form of mean and standard
deviation (SD) or median and first (Q1) and third quartiles (Q3) are
provided for continuous baseline variables, and percentage of total
were generated for categorical baseline variables. Estimated glomerular
filtration rate (eGFR) was calculated using the four-variable Modifica-
tion of Diet in Renal Disease (MDRD) equation for IDMS (isotope
dilution mass spectrometry)-calibrated serum creatinine: eGFR
(mL/min/1.73 m2) ¼ 175 × [serum creatinine in mg/dL]21.154 ×
age20.203 × 1.212 [if black] × 0.742 [if female].
Descriptive summary statistics are provided using SASw software
version 9.2. No statistical comparisons have been made.
Results
Enrolment
Between 13 June 2006 and 4 May 2012, a total of 2278 patients
were randomized at 453 sites in 33 countries representing all
major regions of the world. The three regions with the greatest
contribution were North America (n ¼ 644), Western Europe
(n ¼ 609), and Central/Eastern Europe (n ¼ 454). The three coun-
tries with the largest enrolment were the USA (n ¼ 601), India
(n ¼ 299), and Russia (n ¼ 105). The mean number of patients en-
rolled per site was 5.0 (range per country from 1.3 to 11.1).
Baseline demographics
Table 1 shows the baseline characteristics of the patients in
RED-HF compared with those of patients in other recently pub-
lished heart failure trials.33– 36 At baseline, patients in RED-HF
were older, a much larger proportion were women, and more
were black than in the other trials. Patients in RED-HF also had
a longer duration of heart failure than reported in previous trials.
Co-morbidities
Two co-morbidities were more common at baseline in RED-HF,
specifically diabetes mellitus and impaired renal function (eGFR
,60 mL/min/1.73 m2). The only other notable difference was
the much smaller proportion of current smokers in RED-HF, com-
pared with the other trials. In addition to the co-morbidities shown
in Table 1, 8% of patients had a history of cancer.
Functional capacity and heart failure signs
At baseline, a greater proportion of patients in RED-HF were in
NYHA functional class III or IV than in the other recent trials.
As shown in Table 2, more patients in RED-HF had signs of conges-
tion than those in other trials.37– 40
Quality of life
Table 3 shows KCCQ scores for patients in RED-HF, compared
with those of patients in other recently published trials. The base-
line Overall Summary Score and Clinical Summary Score for
RED-HF patients was 56.1 and 59.4, respectively. These are con-
sistent with patients in RED-HF having moderate to severe heart
failure.34,41– 44
Baseline treatment
Overall, the patients were well treated at randomization and the
pharmacological therapy at baseline was broadly similar to other
recent trials, taking account of study-specific inclusion/exclusion
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Age (mean) 69 60 66 66 70 (11.4)
Female sex (%) 22 23 17 30 41
NYHA class (%)
II 100 49 80 69 35
III 0 50 20 30 63
IV 0 2 – 1 2
Race (%)
White 83 89 – 61 68
Black 2 – – 1 9
Asian 12 8 – 22 14
Other 3 3 – 16 9
Heart rate (mean) 72 80 – 72 72 (11.2)
BP (mean)
Systolic 124 122 – 125 120 (18.0)
Diastolic 75 76 – 72 69 (11.0)
LVEF (mean) 26 29 23 33 30 (6.8)
QRS duration (mean) 122 – 158 – 121 (39.4)
BMI (mean) 28 28 – 27 27 (5.7)
Principal cause of HF (%)
IHD 69 67 67 – 72
Non-IHD 31 33 33 – 28
Duration of HF (years) 4.7 3.5 – – 5.3 (5.4)
Medical history (%)
Hospitalization for HF 53 100b 25c – 87 (37c)
Hypertension 66 67 45 60 74
Angina pectoris 43 – – 65 (IHD) 32
Unstable angina – – – – 21
Myocardial infarction 50 56 – – 54
PCI 22 – 24 – 28
CABG 19 – 34 – 28
Atrial fibrillation/flutter 31 8d 13e 28 32
LBBBf 27 – 72 – 19
Diabetes mellitus 31 31 34 31 46
Stroke 10 8 – – 8
Current smoker – 18 14 – 4
Renal function
Serum creatinine (mmol/L) 102 – – 97 131 (49.3)
eGFR mL/min/1.73 m2 (mean) 71 75 61 – 50 (21.3)
eGFR ,60 mL/min/1.73 m2
(%)
33 – 50 – 72
Treatment (%)
Diuretic 85 – 85 77 91
ACEi 78 79 – NA 63
ARB 19 14 – NA 28
ACEi, ARB, or both 94 – 97 NA 89
Beta-blocker 87 90 90 72 85
MRA NA 60 42g 38 45
Digoxin 27 22 35 42 29
Antithrombotic – – – 33 27
Continued
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criteria (Table 1). Of note, use of antithrombotic and antiplatelet
therapy was not more common in RED-HF than in the other
trials. ICD and CRT use was also consistent with other recent
trials. However, device use was greater in North America and
Western Europe than elsewhere (Table 4).
Haematological and other laboratory
measurements
Apart from haemoglobin, haematocrit, and erythrocyte count
which were reduced, as expected, the median values for other
haematological indices were within the normal range, as were
vitamin B12 and folate levels (Table 5). The proportion of women
with serum iron, total iron-binding capacity (TIBC), ferritin, and
TSAT within the normal range (97, 94, 88, and 97%, respectively)
was numerically higher than for men (89, 92, 83, and 73%, respect-
ively). The notable difference in proportion with a normal TSAT
reflects the higher lower limit of normal for men (20% vs. 15%
in women) and the eligibility TSAT criterion ( ≥ 15%).30 Blood
chemistry was largely as anticipated, with an elevated urea
(blood urea nitrogen) in keeping with the high prevalence of sub-
jects with a low eGFR.
Discussion
Comparison of patient baseline characteristics across trials has to
be made cautiously because these are partly determined by












Vitamin K antagonist – – 34h – 27
Antiplatelet
Aspirin – – 67 51 58
Clopidogrel – – 16 – 20
Any – – – – 66
Antithrombotic or antiplatelet 88 – – – 84
Lipid lowering 62 58i 68i 39i 62i
CRT 2 1 – – 2
ICD 13 4 – – 14
CRT-D 6 – – 9
ACEi, ACE inhibitor; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable
cardioverter defibrillator; IHD, ischaemic heart disease; MRA, mineralocorticoid receptor antagonist; NA, not applicable.
aMedian.
bPer protocol, all patients had an admission for worsening heart failure within 12 months.
cIn previous 6 months.
dCurrent AF excluded.
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Table 2 Clinical signs in RED-HF and other heart failure trials
Peripheral oedema (%) Lung crackles/rales (%) Jugular venous distension (%) Third heart sound (%)
RED-HF (n ¼ 2278) 36 22 20 14
CARE-HF (n ¼ 813) 18 12 18 20
COMET (n ¼ 3029) 13 9 NR 19
MERIT-HF (n ¼ 3991) 15 11 14 23
CHARM-Added (n ¼ 2548) 23 15a 11b 18
CHARM-Alt. (n ¼ 2028) 26 16a 10b 16
Alt., Alternative; NR, not reported.
aBasilar.
b . 6 cm.
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protocol inclusion and exclusion criteria and geographical factors,
as well as the time period during which the trial was recruited (as
the standard of care changes with time). Nevertheless, there are
some differences between patients in RED-HF and those in
other trials that almost certainly reflect the impact of anaemia.
For example, patients enrolled in RED-HF are older than in most
previous trials with a similar inclusion age range, and RED-HF
has a much higher proportion of females than previous studies in
systolic heart failure. These characteristics are consistent with
the finding that anaemia is more common in older subjects and
women in general, and in heart failure specifically. Similarly,
anaemia is associated with worse functional class (although it is
not known which is the ‘chicken’ and which is the ‘egg’). In
keeping with this, we found that a higher proportion of patients
in RED-HF were in NYHA class III and IV at baseline than in
other recent trials. In addition, RED-HF patients had more signs
of congestion, particularly peripheral oedema, than reported in
previous studies. The KCCQ Overall and Clinical Summary
Scores in RED-HF were consistent with generally worse clinical
status than in several recent heart failure trials, including
MADIT-CRT, SHIFT, and HF-ACTION (although the scores
were not as low as in the Heart Mate II trial which enrolled
patients with advanced heart failure ineligible for transplant-
ation).34,41– 44
Diabetes and impaired renal function are associated with an
increased risk of anaemia, and we found both these co-morbidities
to be more common in RED-HF than in the other studies
described.1,9,10 Anaemia is also more prevalent in black individuals,
and RED-HF has enrolled more black patients than in other recent
trials.1,9,10 This could also reflect the higher proportion of US sub-
jects in RED-HF than in the other studies. The longer average dur-
ation of heart failure in patients in RED-HF is also consistent with
the notion that anaemia is more common in more advanced heart
failure (in addition to the studies shown in Table 1, the duration of
heart failure was 3.1 years in BEST and 4.3 years in Val-HeFT).1,9,10
Most other characteristics at baseline did not differ strikingly
between patients in RED-HF and other study populations. The
one exception was the lower prevalence of smoking in RED-HF.
Although this could be a chance finding (or due to under-reporting
of smoking in certain regions/cultures), review of current smoking
rates in five other trials showed a prevalence which ranged from
10.6% to 17.5%.5,38–40,45 The prevalence of smoking in RED-HF
may, therefore, be unusually low, possibly reflecting the association
between smoking and higher haemoglobin levels.
Baseline use of an ACE inhibitor (or ARB) and beta-blocker in
RED-HF was high and consistent with the use of these drugs in
other recent trials. Mineralocorticoid receptor antagonist (MRA)
use at baseline was not as high as in SHIFT, but all patients in that
trial had recently been hospitalized, i.e. probably recently in NYHA
class IV and with a firm indication for an MRA.34 The majority were
also enrolled in Europe and none in the USA; MRA use is generally
lower in the USA compared with Europe (and RED-HF enrolled a
high proportion of patients in the USA). The higher prevalence of
renal dysfunction in RED-HF may also have limited use of MRAs.
One other recent trial also makes for an interesting comparison
with RED-HF. FAIR-HF enrolled 459 patients with NYHA functional
class II or III heart failure, an LVEF ≤ 40% (for patients with NYHA
class II) or ≤ 45% (for NYHA class III), iron deficiency (defined as a
ferritin level ,100 mg/L or between 100 and 299 mg/L, if the TSAT
was ,20%), and a haemoglobin level of 9.5–13.5 g/dL.46 Patients
were randomized 1:2 to i.v. saline or i.v. iron. At baseline, the mean
level of ferritin in FAIR-HF was 55 mg/L (compared with 156 mg/L
in RED-HF), TSAT 17.4% (compared with 26.9%), and haemoglobin
11.9 g/dL (compared with 11.0 g/dL). Patients in FAIR-HF had a
higher average eGFR at baseline (64 mL/min/1.73 m2) compared
with those in RED-HF (50 mL/min/1.73 m2).
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Table 3 Baseline mean (SD) Kansas City Cardiomyopathy Questionnaire Overall Summary Scores and Clinical













OSS 77 66 65 56 (22.5) 54 27
CSS 81 – 68 59 (22.4) 64 34
CSS, Clinical Summary Score; OSS, Overall Summary Score.
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Table 4 Type of device used by region
North America
(n 5 644), n (%)
Latin America
(n 5 262), n (%)
Western Europe/AUS/RSA/
Israel (n 5 609), n (%)
Eastern Europe/Russia
(n 5 454), n (%)
Asia (n 5 309),
n (%)
CRT only 8 (1) 4 (2) 19 (3) 3 (1) 4 (1)
CRT-D 133 (21) 1 (,1) 70 (11) 6 (1) 4 (1)
ICD 214 (33) 8 (3) 72 (12) 12 (3) 3 (1)
None 289 (45) 249 (95) 448 (74) 433 (95) 298 (96)
AUS, Australia; RSA, Republic of South Africa; Asia, India and Hong Kong; Latin America, Argentina, Brazil, Chile, and Mexico.
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In summary, the patients enrolled in RED-HF exhibit the
expected greater functional impairment and co-morbidities found
in patients with anaemia in addition to heart failure and are well
treated with conventional evidence-based therapy. Therefore,
RED-HF is well placed to answer the question of whether or
not the addition of darbepoetin alfa to standard therapy will
have an incremental benefit in patients with systolic heart failure
and anaemia.
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Argentina (82 patients): M. Amuchastegui, C. Belziti, J. Bluguermann, M.
Caccavo, L. Cartasegna, R. Colque, C. Cuneo, A. Fernandez, A. Gabito,
R. Goicochea, M. Gonzalez, V. Gorosito, L. Grinfeld, M. Hominal, R.
Kevorkian, M. Litvak Bruno, J. Llanos, I. Mackinnon, O. Manuale, E. Mar-
zetti, D. Nul, E. Perna, M. Riccitelli, A. Sanchez, D. Santos, P. Schygiel, J.
Toblli, D. Vogel.
Australia (23 patients): A. Aggarwal, J. Amerena, F. De Looze,
P. Fletcher, D. Hare, M. Ireland, H. Krum, J. Lattimore, T. Marwick,
A. Sindone, P. Thompson, J. Waites.
Austria (8 patients): J. Altenberger, C. Ebner, K. Lenz, R. Pacher, G.
Poelzl.
Belgium (70 patients): F. Charlier, M. de Ceuninck, G. De Keulenaer,
P. Dendale, P. Maréchal, W. Mullens, J. Thoeng, M. Vanderheyden,
J. Vanhaecke, C. Weytjens, B. Wollaert.
Brazil (69 patients): D. Albuquerque, D. Almeida, J. Aspe y Rosas, E.
Bocchi, S. Bordignon, N. Clausell, S. Kaiser, P. Leaes, S. Martins Alves,
M. Montera, L. Moura, R. Pereira de Castro, S. Rassi, A. Reis, J. Saraiva,
M. Simões, J. Souza Neto, M. Teixeira.
Bulgaria (90 patients): H. Benov, B. Chompalova, T. Donova, P.
Georgiev, D. Gotchev, A. Goudev, M. Grigorov, D. Guenova,
V. Hergeldjieva, D. Ivanov, E. Kostova, A. Manolova, S. Marchev, F.
Nikolov, A. Popov, D. Raev, M. Tzekova.
Canada (43 patients): W. Czarnecki, N. Giannetti, H. Haddad,
J. Heath, T. Huynh, S. Lepage, P . Liu, E. Lonn, P. Ma, D. Manyari,
G. Moe, J. Parker, Y. Pesant, M. Rajda, J. Ricci, S. Roth, F. Sestier,
V. Sluzar, B. Sussex, S. Vizel.
Chile (14 patients): G. Antezana, C. Bugueno, P. Castro, C. Cone-
jeros, L. Manriquez, D. Martinez, S. Potthoff, B. Stockins, J. Vukasovic.
Czech Republic (15 patients): P. Gregor, M. Herold, O. Jerabek,
R. Jirmar, R. Kuchar, A. Linhart, B. Podzemska, M. Soucek, J. Spac,
R. Spacek, P. Vodnansky.
Denmark (29 patients): J. Bronnum-Schou, K. Clemmensen, K.
Egstrup, G. Jensen, L. Kjoller-Hansen, L. Kober, J. Markenvard,
J. Rokkedal, K. Skagen, C. Torp-Pedersen, C. Tuxen, L. Videbak.
Estonia (6 patients): T. Laks, V. Vahula.
Finland (0 patients): V. Harjola, R. Kettunen, M. Kotila.
France (48 patients): F. Bauer, A. Cohen Solal, D. Coisne, J. Davy,
P. De Groote, P. Dos Santos, F. Funck, M. Galinier, P. Gibelin,
R. Isnard, Y. Neuder, G. Roul, R. Sabatier, J. Trochu.
Germany (99 patients): S. Anker, S. Denny, T. Dreykluft, M. Flesch, S.
Genth-Zotz, R. Hambrecht, J. Hein, M. Jeserich, M. John, H. Kreider-
Stempfle, U. Laufs, K. Muellerleile, M. Natour, M. Sandri, T. Schäufele,
E. von Hodenberg, K. Weyland, B. Winkelmann.
Hong Kong SAR (10 patients): H. Tse, B. Yan.
Hungary (8 patients): B. Barsi, J. Csikasz, C. Dezsi, I. Edes, T. Forster,
P. Karpati, C. Kerekes, E. Kis, I. Kosa, G. Lupkovics, A. Nagy, I. Preda,
A. Ronaszeki, J. Tomcsanyi, K. Zamolyi.
India (299 patients): D. Agarwal, V. Bahl, A. Bordoloi, K. Chockalin-
gam, M. Chopda, V. Chopra, J. Dugal, N. Ghaisas, S. Ghosh, P. Grant, S.
Hiremath, S. Iyengar, B. Jagadeesa Subramania, P. Jain, A. Joshi, A. Khan,
A. Mullasari, S. Naik, A. Oomman, V. Pai, R. Pareppally Gopal, K. Parikh,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Baseline laboratory measurements in RED-HF
Measurement Median (Q1, Q3)
Haematology
Haemoglobin (g/L) 112 (106, 117)
Haematocrit (%) 0.34 (0.33, 0.36)
White cells (109/L) 6.5 (5.3, 7.9)
Red cells (1012/L) 5.3 (4.4, 6.1)
Platelets (109/L) 224 (179, 275)
Iron indices
Serum iron (mmol/L) 12.2 (9.8, 15.8)
TIBC (mmol/L) 50.5 (44.8, 56.7)
Ferritin (mg/L) 102 (53, 194)
TSAT (%) 24 (19, 31)
Vitamin levels
Vitamin B12 (pmol/L) 286 (206, 454)
Serum folate (nmol/L) 24 (14, 56)
Blood chemistry
Sodium (mmol/L) 140 (138, 142)
Potassium (mmol/L) 4.5 (4.2, 4.9)
Magnesium (mmol/L) 0.9 (0.8, 1.0)
BUN/urea (mmol/L) 10.4 (7.1, 15.0)
Uric acid (mmol/L) 440 (357, 547)
Albumin (g/L) 39 (36, 42)
Calcium (mmol/L) 2.4 (2.3, 2.5)
Phosphorus (mmol/L) 1.2 (1.1, 1.3)
Glucose (mmol/L) 6.1 (5.3, 8.4)
HbA1c (%) 6.0 (5.6, 7.0)
Total cholesterol (mmol/L) 4.1 (3.4, 4.9)
BUN, blood urea nitrogen; HbA1c, glycated haemoglobin; TIBC, total iron-binding
capacity; TSAT, transferrin saturation.
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T. Patel, V. Prakash, B. Sastry, S. Sathe, N. Sinha, V. Srikanthan,
P. Subburamakrishnan, H. Thacker, G. Wander.
Israel (37 patients): D. Admon, A. Katz, E. Klainman, B. Lewis, A.
Marmor, M. Moriel, M. Mosseri, A. Shotan, J. Weinstein, R. Zimlichman.
Italy (51 patients): P. Agostoni, M. Albanese, G. Alunni, R. Bini,
A. Boccanelli, L. Bolognese, C. Campana, E. Carbonieri, C. Carpino,
L. Checco, F. Cosmi, G. D’Angelo, M. De Cristofaro, A. Floresta,
A. Fucili, M. Galvani, A. Ivleva, S. Marra, G. Musca, N. Peccerillo,
P. Perrone Filardi, E. Picchio, T. Russo, L. Scelsi, M. Senni, L. Tavazzi.
Latvia (20 patients): A. Erglis, I. Jasinkevica, N. Kakurina, I. Veze, E.
Volans.
Lithuania (30 patients): A. Bagdonas, E. Berukstis, J. Celutkiene, A.
Dambrauskaite, D. Jarasuniene, D. Luksiene, A. Rudys, G. Sakalyte, S.
Sliaziene.
Mexico (97 patients): R. Aguilar-Romero, J. Aspe y Rosas, E.
Cardona-Muñoz, J. Castro-Jimenez, J. Chavez-Herrera, E. Chuquiure
Valenzuela, G. De la Pena, E. Herrera, J. Leiva-Pons, A. Lopez Alvarado,
G. Mendez Machado, G. Ramos-Lopez.
The Netherlands (64 patients): D. Basart, E. Buijs, J. Cornel, M. de
Leeuw, R. Dijkgraaf, P. Dunselman, M. Freericks, K. Hamraoui, T. Len-
derlink, G. Linssen, P. Lodewick, C. Lodewijks, D. Lok, P. Nierop, E.
Ronner, A. Somsen, J. van Dantzig, P. van der Burgh, L. van Kempen,
B. van Vlies, A. Voors, A. Wardeh, F. Willems.
Norway (17 patients): K. Dickstein, T. Gundersen, T. Hole, J. Thal-
amus, A. Westheim.
Poland (92 patients): M. Dabrowski, J. Gorski, J. Korewicki, K. Kuc,
P. Miekus, W. Musial, J. Niegowska, W. Piotrowski, P. Podolec,
L. Polonski, P. Ponikowski, A. Rynkiewicz, R. Szelemej, M. Trusz-Gluza,
M. Ujda, D Wojciechowski, A. Wysokinski.
Portugal (14 patients): A. Camacho, C. Fonseca, P. Monteiro.
Romania (26 patients): E. Apetrei, I. Bruckner, E. Carasca, I. Coman,
M. Datcu, S. Dragulescu, P. Ionescu, D. Iordachescu-Petica, I. Manitiu, V.
Popa, A. Pop-Moldovan, M. Radoi, S. Stamate, M. Tomescu, I. Vita.
Russia (105 patients): G. Aroutiounov, M. Ballyuzek, B. Bart, S.
Churina, M. Glezer, B. Goloshchekin, A. Ivleva, Z. Kobalava, V. Kos-
tenko, Y. Lopatin, A. Martynov, V. Orlov, E. Semernin, Z. Shogenov,
B. Sidorenko, A. Skvortsov, G. Storzhakov, V. Sulimov, O. Talibov, S.
Tereshenko, V. Tsyrline, V. Zadionchenko, D. Zateyshchikov.
Slovakia (62 patients): A. Dzupina, M. Hranai, J. Kmec, K. Micko,
J. Murin, D. Pella, G. Sojka, V. Spisak, P. Vahala, D. Vinanska.
South Africa (25 patients): A. Badat, J. Bayat, S. Dawood, E. Delport,
G. Ellis, R. Garda, E. Klug, T. Mabin, D. Naidoo, M. Pretorius, N. Ranjith,
L. Van Zyl, H. Weich.
Spain (40 patients): M. Anguita, J. Berrazueta, J. Bruguera i Cortada,
E. de Teresa, M. Gómez Sánchez, J. González Juanatey, I. Gonzalez-
Maqueda, R. Jordana, J. Lupon, L. Manzano, D. Pascual Figal,
L. Pulpón, J. Recio, F. Ridocci Soriano, J. Rodrı́guez Lambert, E. Roig
Minguell, E. Roig Minguell, J. Romero, P. Valdovinos.
Sweden (19 patients): L. Klintberg, T. Kronvall, M. Lycksell, S.
Morner, E. Rydberg, K. Swedberg, I. Timberg, G. Wikstrom
Switzerland (0 patients): T.4 Moccetti.
UK (65 patients): J. Ashok, P. Banerjee, G. Carr-White, J. Cleland, E.
Connolly, M. Francis, R. Greenbaum, H. Kadr, S. Lindsay, J. McMurray,
S. Megarry, A. Memon, D. Murdoch, R. Senior, I. Squire, L. Tan, K.
Witte.
USA (601 patients): K. Adams, P. Adamson, A. Adler, L. Altschul, A.
Altschuller, H. Amirani, I. Anand, C. Andreou, M. Ansari, M. Anto-
nishen, H. Banchs, S. Banerjee, D. Banish, A. Bank, A. Barbagelata, D.
Barnard, R. Bellinger, A. Benn, M. Berk, B. Berry, V. Bethala, S. Bilazar-
ian, J. Bisognano, F. Bleyer, M. Blum, J. Boehmer, A. Bouchard, A. Boyle,
B. Bozkurt, C. Brown, B. Burlew, K. Burnham, J. Butler, J. Call, P.
Cambier, T. Cappola, R. Carlson, B. Chandler, R. Chandra, P.
Chandraratna, R. Chernick, D. Colan, H. Colfer, W. Colucci, T. Con-
nelly, O. Costantini, S. Dadkhah, I. Dauber, J. Davis, S. Davis, S.
Denning, M. Drazner, S. Dunlap, L. Egbujiobi, U. Elkayam, J. Elliott,
M. El-Shahawy, L. Essandoh, G. Ewald, J. Fang, H. Farhoud, G. Felker,
J. Fernandez, R. Festin, G. Fishbein, V. Florea, E. Flores, J. Floro, M.
Gabris, M. Garg, R. Gatewood, M. Geller, J. Ghali, W. Ghumman, G.
Gibbs, E. Gillespie, R. Gilmore, H. Gogia, L. Goldberg, I. Gradus-Pizlo,
T. Grainger, G. Gudmundsson, D. Gunawardena, D. Gupta, T. Hack, S.
Hall, G. Hamroff, S. Hankins, M. Hanna, J. Hargrove, W. Haught, P.
Hauptman, M. Hazelrigg, C. Herzog, J. Heywood, T. Hill, T. Hilton,
H. Hirsch, J. Hunter, H. Ibrahim, M. Imburgia, B. Iteld, B. Jackson, N. Jaf-
frani, D. Jain, A. Jain, M. James, J. Jimenez, E. Johnson, P. Kale, A. Kane-
shige, S. Kapadia, D. Karia, R. Karlsberg, R. Katholi, E. Kerut, W. Khoury,
R. Kipperman, M. Klapholz, E. Kosinski, M. Kozinn, D. Kraus, S. Krueger,
H. Krum, S. Kumar, E. Lader, C. Lee, W. Levy, E. Lewis, K. Light-
McGroary, I. Loh, W. Lombardi, C. Machado, F. Maislos, D. Mancini,
T. Markus, P. Mather, K. McCants, F. McGrew, B. McLaurin, E. McMillan,
D. McNamara, T. Meyer, S. Meymandi, A. Miller, E. Minami, M. Modi, F.
Mody, P. Mohanty, R. Moscoso, R. Moskowitz, M. Moustafa, M. Mullen,
T. Naz, T. Noonan, T. O’Brien, W. Oellerich, R. Oren, S. Pamboukian,
N. Pereira, W. Pitt, C. Porter, S. Prabhu, S. Promisloff, R. Ratkovec, R.
Richardson, A. Ross, N. Saleh, M. Saltzberg, S. Sarkar, J. Schmedtje, R.
Schneider, G. Schuyler, J. Shanes, A. Sharma, C. Siegel, R. Siegel, D.
Silber, V. Singh, N. Singh, J. Singh, J. Sklar, R. Small, A. Smith, E.
Smith, E. Smith, D. Smull, R. Sotolongo, C. Staniloae, D. Stapleton, P.
Steele, J. Stehlik, M. Stein, W. Tang, U. Thadani, G. Torre-Amoine, B.
Trichon, C. Tsai, R. Tummala, A. Van Bakel, R. Vicari, N. Vijay, K.
Vijayaraghavan, T. Vittorio, M. Vossler, L. Wagoner, D. Wallis, N.
Ward, M. Widmer, J. Wight, C. Wilkins, C. Williams, G. Williams, M.
Winchester, E. Winkel, B. Wittmer, D. Wood, D. Wormer, R.
Wright, Z. Xu, M. Yasin, R. Zolty.
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